Holen Sie sich die Stockscreener-App
29.72
1.37%
0.23
Schlusskurs vom Vortag:
$29.49
Offen:
$29.65
24-Stunden-Volumen:
220.02K
Relative Volume:
0.58
Marktkapitalisierung:
$1.80B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-118.12M
KGV:
-13.03
EPS:
-2.2802
Netto-Cashflow:
$-82.63M
1W Leistung:
+6.92%
1M Leistung:
+13.07%
6M Leistung:
+58.09%
1J Leistung:
+57.26%
1-Tages-Spanne:
$29.11
$30.25
1-Wochen-Bereich:
$27.35
$31.27
52-Wochen-Spanne:
$16.00
$34.48
Oculis Holding Ag Stock (OCS) Company Profile
Firmenname
Oculis Holding Ag
Sektor
Branche
Telefon
-
Adresse
-
Compare OCS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
29.74 | 1.78B | 0 | -118.12M | -82.63M | -2.2802 |
VRTX
Vertex Pharmaceuticals Inc
|
436.52 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.88 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.13 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.74 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.40 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-19 | Eingeleitet | JP Morgan | Overweight |
| 2025-08-27 | Eingeleitet | Needham | Buy |
| 2023-12-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-10-05 | Eingeleitet | Stifel | Buy |
| 2023-06-14 | Eingeleitet | BofA Securities | Buy |
| 2023-06-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-06-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-10 | Eingeleitet | Pareto | Buy |
| 2023-04-28 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Oculis Holding Ag Aktie (OCS) Neueste Nachrichten
How Investors May Respond To Oculis (OCS) Q1 Loss, Governance Moves And Guggenheim Pipeline Spotlight - simplywall.st
OCS Stock Price, Quote & Chart | OCULIS HOLDING AG (NASDAQ:OCS) - ChartMill
OCS Initiates Coverage On Guggenheim -- Price Target Announced a - GuruFocus
Oculis Holding AG Warrants (OCSAW) Live Share Price, Invest From India - INDmoney
Guggenheim Initiates Oculis Holding at Buy With $75 Price Target - marketscreener.com
OCS Technical Analysis & Stock Price Forecast - Intellectia AI
Guggenheim initiates Oculis stock with buy rating on DME treatment potential - Investing.com Nigeria
Guggenheim initiates coverage of Oculis Holding (OCS) with buy recommendation - MSN
Strength Seen in Oculis Holding AG (OCS): Can Its 6.7% Jump Turn into More Strength? - MSN
Oculis FDA SPA Sharpens Privosegtor Phase 3 Path And Investor Focus - Sahm
OCS Maintained by JP Morgan -- Price Target Raised to $42.00 - GuruFocus
(OCS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewswire
Oculis Holding AG (OCS) reports Q1 loss, lags revenue estimates - MSN
TradingKey - TradingKey
Oculis AGM Backs All Proposals, Adds Veteran Biotech CFO to Board and Expands Capital Flexibility - TipRanks
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors - marketscreener.com
Oculis (NASDAQ: OCS) clears AGM, adds new director and treasury share capacity - Stock Titan
Oculis Holding Ag Announces Board and Committee Changes - marketscreener.com
Oculis's global DME consensus study identifies critical gaps in care - Eyes On Eyecare
HC Wainwright Issues Positive Forecast for Oculis Earnings - MarketBeat
Oculis birtir niðurstöður aðalfundar 2026 og tilkynnir um kjör Gregory D. Perry í stjórn félagsins - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
H.C. Wainwright raises Oculis stock price target to $47 on trial progress - Investing.com UK
Q1 Earnings Forecast for Oculis Issued By HC Wainwright - MarketBeat
OCS: All agenda items passed, with strong financials and major clinical milestones on track - TradingView
Oculis Releases First Quarter 2026 Financial Results, Provides Company Update - VisionMonday.com
Is Oculis (OCS) Turning Regulatory Momentum In Ophthalmology Into A Durable Competitive Edge? - simplywall.st
FDA agrees to special protocol assessment for Oculis’s phase 3 ON trial - Eyes On Eyecare
Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Oculis Holding AG (NASDAQ:OCS) Q1 Earnings Miss Overshadowed by Key Pipeline Catalysts - ChartMill
Oculis Reports Strong Liquidity in Q1 2026 Unaudited Results - TipRanks
Oculis Reports Q1 2026 Financial Results and Provides Company Update - The Manila Times
Oculis (NASDAQ: OCS) advances late-stage eye pipeline with CHF 222m cash - Stock Titan
Press Release: Oculis Reports Q1 2026 Financial Results and Provides Company Update - Moomoo
Weighing Oculis Holding (NasdaqGM:OCS) Rich P/B Against DCF Upside After Strong Multi Year Share Gains - Yahoo Finance
Oculis stock gains after FDA trial design agreement By Investing.com - Investing.com Australia
Oculis stock gains after FDA trial design agreement - Investing.com India
Number of shareholders of Oculis Holding AG – NASDAQ:OCS - TradingView
Oculis secures FDA agreement on trial design for Privosegtor in optic neuritis treatment - Pluang
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial - The Manila Times
Oculis Holding AG Receives FDA Special Protocol Assessment for Privosegtor's PIONEER-1 Trial in Optic Neuritis Treatment - Quiver Quantitative
Oculis gets FDA agreement on study design for optic neuritis drug - Stock Titan
(OCS) Risk Channels and Responsive Allocation - Stock Traders Daily
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting - The Manila Times
60% go untreated in DME; Oculis nears June eye-drop data - Stock Titan
Oculis (OCS) to Release Earnings on Monday - MarketBeat
Oculis Nears Key Milestone as Phase 3 OCS-01 Eye Drop Trial in Diabetic Macular Edema Completes - TipRanks
H.C. Wainwright raises Oculis stock price target to $44 on trial progress - Investing.com
Gildi lifeyrissjodur Makes New Investment in Oculis Holding AG $OCS - MarketBeat
Finanzdaten der Oculis Holding Ag-Aktie (OCS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):